Financial Contrast: Pluri (NASDAQ:PLUR) versus Sernova Biotherapeutics (OTCMKTS:SEOVF)

Sernova Biotherapeutics (OTCMKTS:SEOVF) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Risk and Volatility

Sernova Biotherapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sernova Biotherapeutics and Pluri, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sernova Biotherapeutics	0	0	0	0	0.00
Pluri	0	0	1	0	3.00

Pluri has a consensus target price of $12.00, suggesting a potential upside of 132.56%. Given Pluri’s stronger consensus rating and higher probable upside, analysts plainly believe Pluri is more favorable than Sernova Biotherapeutics.

Profitability

This table compares Sernova Biotherapeutics and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sernova Biotherapeutics	N/A	N/A	-396.49%
Pluri	-2,563.29%	-4,191.91%	-85.40%

Earnings & Valuation

This table compares Sernova Biotherapeutics and Pluri”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sernova Biotherapeutics	N/A	N/A	-$23.65 million	($0.04)	-3.50
Pluri	$330,000.00	123.06	-$20.89 million	($5.53)	-0.93

Pluri has higher revenue and earnings than Sernova Biotherapeutics. Sernova Biotherapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

16.6% of Pluri shares are held by institutional investors. 25.9% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Pluri beats Sernova Biotherapeutics on 9 of the 13 factors compared between the two stocks.

About Sernova Biotherapeutics

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.